Armata Q3 loss from ops $(10.3)M; cash $24M; AP-SA02 and AP-PA02 enrollment accelerating

Armata Pharmaceuticals, Inc.

2023-Q3 EPS reported -$1.36

Grant revenue $1.2M (vs $1.3M); R&D $8.0M (vs $8.4M); G&A $3.6M (vs $1.6M) due to one-time financing costs.
Loss from operations widened to $(10.3)M from $(8.6)M YoY.
Cash $24.0M as of Sept 30 vs $14.9M Dec 31, 2022; $25M credit agreement with Innoviva signed July 2023.
Phase 2a diSArm (AP-SA02) and Phase 2 Tailwind (AP-PA02) enrollment accelerating; expects Phase 2 diSArm completion in 2024.
Shares outstanding ~36.1M as of Nov 14, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Armata Pharmaceuticals, Inc. reported three months ended September 30, 2023 results: revenue grant revenue of approximately $1.2 million.

Period: three months ended September 30, 2023
Revenue: grant revenue of approximately $1.2 million
Result: reported results

Exact text from the filing

through the remainder of the year and into 2024,” Dr. Birx concluded. Third Quarter 2023 Financial Results Grant Revenue. The Company recognized grant revenue of approximately $1.2 million for the three months ended September 30, 2023, which represents Medical Technology Enterprise Consortium (“MTEC”)’s share of the costs incurred for the Company’s AP-SA02 program

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Armata Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-019016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.